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We performed this study to measure the Tumor Necrosis Factor-alpha (TNF-α) plasma level 
and to survey its correlation with disease activity in the newly diagnosed Rheumatoid Arthritis 
(RA) patients and those who were under treatment with the combination of Disease-Modifying 
Anti-Rheumatic Drug (DMARD) plus Prednisolone (PSL).We enrolled 30 newly diagnosed RA 
patients who received no treatment regarding their disease, 30 patients under treatment with the 
combination of Methotrexate (MTX) + Hydroxychloroquine (HCQ) + PSL and 30 healthy subjects 
in this case-control study from September 2017 to December 2017. The level of plasma TNF-α 
was measured by enzyme-linked immunosorbent assay (ELISA) in each group. For assessment of 
disease severity, we used Disease Activity Score-28 (DAS-28) formula, and regarding DAS-28, 
we divided patients into four groups, including remission, low, moderate and high disease activity. 
There were no significant differences in the plasma level of TNF-α between the newly diagnosed 
RA patients and subjects who received MTX + HCQ + PSL, as well as healthy controls (p>0.05). 
There was a significant correlation between plasma levels of TNF-α and DAS-28 in the newly 
diagnosed patients with RA (r = 0.594, P = 0.001). Targeting TNF-α at the early stage of RA could 
have more beneficial effects on the amelioration of disease activity.
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INTRODUCTION
Rheumatoid arthritis (RA) is considered as prevalent 
chronic inflammatory disorder with a significant social 
and economic burden (Choy, Panayi, 2001). The clinical 
presentation of RA is very heterogeneous and consists 
of the variety of signs and symptoms including joint 
inflammation and various extra-articular manifestations 
(Stanich et al., 2009). Pro-inflammatory cytokines 
are among soluble mediators with a crucial role in the 
pathogenesis of rheumatoid arthritis (Vervoordeldonk, 
Tak, 2002). TNF-α is one of these cytokines with potent 
inflammatory effects in the pathogenesis of synovitis 
(Butler et al., 1995). The effectiveness of anti-TNF-α 
monoclonal antibodies in the treatment of RA highlights 
its importance in RA pathogenesis (Firestein, 2016). 
Traditional disease- modifying anti-rheumatic drugs 
(DMARDs) especially methotrexate (MTX) are the 
cornerstone of RA treatment (O’Dell et al., 1996). The 
anti-inflammatory effect of DMARDs including MTX, 
hydroxychloroquine (HCQ), and sulfasalazine (SSZ) 
could be attributed directly or indirectly to inhibition 
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of pro-inflammatory cytokine and chemokines release 
(Seitz et al., 1995, Karres et al., 1998, Gronberg, 1994). 
TNF-α induces production of other pro-inflammatory 
cytokines such as IL-1 in the inflamed synovium and 
also acts as a chemoattractant for the different cell types 
including T lymphocytes (Green et al., 1998). TNF-α 
also promotes the process of bone resorption through its 
effect on osteoclasts (Lam et al., 2000, Abu-Amer et al., 
1997). Various studies have demonstrated that TNF-α is 
released from synovium and reaches its systemic levels 
in blood and exerts its deleterious effects on several 
tissues (Sattar et al., 2003) Although the role of TNF-α 
as a pro-inflammatory cytokine in the pathogenesis 
of synovial inflammation has been comprehensively 
explored, the effect of its plasma level fluctuation on 
disease activity deserves further investigation (Chu et 
al., 1991, Larsson et al., 2015, Matsuno et al., 2002). The 
purpose of our study was to compare the TNF-α plasma 
levels in the newly established RA and patients who 
received MTX and HCQ combination plus prednisolone 
(PSL) therapy. Furthermore we evaluated the correlation 
between disease activity and plasma concentration of 
TNF-α in each patients group.
METHODS
Patients characteristics
The study was in accordance with the Declaration 
of Helsinki and was conducted with approval from 
the Ethical Committee of Kermanshah University of 
Medical Sciences (KUMS). Patients were selected 
by consecutive sampling between July 2017, and 
October 2017 from Helal Ahmar clinic of Kermanshah 
University of medical sciences. All participants 
signed informed consent and were informed about 
the aim and procedures of this research. All patients 
were diagnosed according to the EULAR/ACR 2010 
classification criteria by an expert rheumatologist. We 
have included 60 patients with rheumatoid arthritis 
including 30 newly diagnosed patients (age, 47.3 ± 2.03 
years; 6 men and 24 women) without any treatment for 
RA and 30 patients (age, 47.9 ± 1.8 years; 6 men and 
24 women) who received Methotrexate (MTX, 7.5- 25 
mg/week), Hydroxychloroquine (HCQ, 200 mg/day) 
combinational therapy plus oral Prednisolone (PSL, 
range from 5-10 mg/day). 
Patients with the history of other rheumatic and 
autoimmune disease, severe infection, cancer and 
pregnant women were excluded from our study. Also, 
30 age- and sex-matched healthy subjects (age, 47.6 ± 
1.9 years; 6 men and 24 women) were included as the 
control group in this survey. 
Plasma sample collection
5 ml peripheral Blood was obtained from each 
patient and healthy controls. Plasma samples were 
separated in (Ethylenediaminetetraacetic Acid) EDTA 
containing tubes and centrifuged at 3000g for 10 minutes 
and was stored in -70° centigrade for later measurement 
of TNF-α. 
The calculation of disease activity score
According to the formula, DAS-28 = 0.56 (TJ) ½ 
+0.28 (SJ) 1/2 +0.70 ln (ESR) +0.014 GH (TJ: Number 
of tender joints from 28 joints; SJ: Number of swollen 
joints from28 joints; GH: global health), patients 
were categorized into four different groups including 
remission (DAS28 ≤ 2.6), low (2.6 < DAS28 ≤ 3.2), 
moderate (3.2 < DAS28 ≤ 5.1) and high (DAS28 > 5.1) 
(Inoue et al., 2007).
Method of measuring plasma TNF-α
Plasma level of TNF-α was measured using 
a sandwich enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer’s instructions 
(IBL kit, Germany). 
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS, 
version 24. The data normality was assessed by the 
Kolmogorov-Smirnov (K-S) test. The Kruskal-Wallis 
Test as a One-way non-parametric ANOVA was used 
to compare the plasma levels of TNF-α among our 
groups. The T-test and Mann-Whitney test were used 
for parametric and non-parametric data respectively. 
Pearson’s correlation test was employed to assess 
the correlations between parametric variables, also 
Spearman rank correlations were applied to test 
the correlation between non-parametric variable. 
In all statistical analysis (p < 0.05) was considered 
statistically significant and the results are expressed as 
the mean ± SEM. 
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RESULTS
Demographic and clinical variables
The demographic and clinical characteristics of 
patients and controls are shown in Table I. Patients 
and controls did not significantly differ in age or sex. 
ESR values and DAS-28 were significantly higher in 
patients without treatment compared to RA patients who 
received the combination of MTX and HCQ plus PLS 
(p = 0.007, p < 0.001, respectively) (Table I).
The mean plasma levels of TNF-α did not differ 
significantly between newly diagnosed RA patients, 
Patients who received the combination of MTX and 
HCQ plus PSL and also with healthy subjects as shown 
in Figure 1. (8.039 ± 2.225 pg/mL, 8.326 ± 2.127 pg/mL, 
7.824 ± 1.752 pg/mL, P = 0.567, respectively). The increasing 
trend in mean plasma levels of TNF-α in subgroups 
of patients with early RA including Remission, low, 
moderate, and high disease activity have been seen (0.00, 
6.7244 ± .37945, 8.7592 ± .63141, 9.5817 ± .64653pg/mL, 
respectively, P = 0.007,) in contrast, there were no 
significant differences among subgroups in RA patients 
treated with the combination of MTX and HCQ plus 
PSL (8.3971 ± .52008, 8.1537 ± 1.17491, 6.8920 ± .24850, 
0.00, pg/mL, P = 0.295, respectively) (Table II). 
The plasma levels of TNF-α had significant 
correlation with DAS-28 In the newly diagnosed patients 
(r = 0.594, P = 0.001) but not in RA patients who were 
under treatment (r = - 0.29, P = 0.12). There was no 
significant correlation between ESR and plasma levels 
of TNF-α in both newly diagnosed and under treatment 
groups as shown in Figure 2 (r = 0.295, P = 0.235; r = 
- 0.185, P = 0.328, respectively).





Treated (n=30) Untreated (n=30)
Age Female (n = 24) 46.13 ± 1.98 46.50 ± 2.07 46.46 ± 2.41
Male (n = 6) 53.67 ± 4.97 53.50 ± 3.54 50.07 ± 3.21
Min/Max 
(age)
Female 26/60 26/64 25/67
Male 40/70 45/67 41/63
5 ± 0.95
Drugs (%)
Prednisolone 0 100 0
Methotrexate 0 100 0
Hydroxychloroquine 0 100 0
Other DMARDS 0 0 0
Tests
ESR (mm/h) 15.17 ± 1.79**  28.63 ± 5.26
Tender joint 1.27 ± 0.24*** 6.23 ± 0.66
Swollen joint 0.73 ± 0.14*** 3.07 ± 0.39
DAS-28 2.43 ± 0.13*** 3.96 ± 0.18
TNF-α (pg/ml) 7.82 ± 1.75 8.04 ± 2.23 8.33 ± 2.13
Data are Mean±SEM; prednisolone dose: 5–10 mg/day, Methotrexatedose: 7.5–25 mg/week, Hydroxychloroquine: 200mg/
day*P < 0.05,**P < 0.01, ***P < 0.001. DAS-28, Disease Activity Score-28; DMARD, disease-modifying anti-rheumatic drug; 
ESR, erythrocyte sedimentation rate; TNF-α, tumor necrosis factor α.
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FIGURE 1 - The plasma levels of tumor necrosis factor-α (TNF-α) in the newly diagnosed rheumatoid arthritis (RA) patients, 
under treatment patients and age and sex-matched healthy subjects.







Remission =< 2.60 0
Low = 2.61-3.20 6.72 ± 0.38 9
Moderate = 3.20-5.10 8.76 ± 0.63* 13
High => 5.10 9.58 ± 0.65** 8
Under treatment
(MTX+HCQ+PSL)
Remission =< 2.60 8.39 ± .52 17
Low = 2.61-3.20 8.15 ± 1.17 7
Moderate = 3.20-5.10 6.89 ± 0.25 6
High => 5.10 0
*p < 0.05 moderate disease activity vs low disease activity in new case patient
**p < 0.001 high disease activity vs low disease activity in new case patient.
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FIGURE 2 - Correlations between study variables. Correlations between TNF-α and DAS-28, TNF-α and ESR, in both new case 
and under treatment RA patients
DISCUSSION
Although the role of the locally produced TNF-α 
in the pathogenesis of synovitis and joint damage has 
been previously determined, the effect of its plasma 
level on RA disease progression warrants further 
investigation. (Chu et al., 1991; Matsuno et al., 2002; 
Georgopoulos, Plows, Kollias, 1996). In our study, 
the mean plasma levels of TNF-α was higher in both 
naive RA patients and patients who received the 
combination of MTX+HCQ+ PSL in comparison with 
healthy subjects, but the statistical differences were not 
significant (P > 0.05).This was contrary to the study 
of Tetta et al. which showed statistically significant 
differences between the plasma levels of TNF-α in RA 
patients and healthy subjects (Tetta et al., 1990). The 
probable cause of this controversy is because of the the 
different method which we used in our study. To measure 
the plasma levels of TNF-α Tetta et al. evaluated the 
cytotoxic activity of this cytokine while we used high 
sensitive ELISA kit which directly measured TNF-α 
with the much lower limit of detection. Similar to our 
results, Beyazal et al. (2017) revealed that the mean 
serum TNF-α levels are similar between RA patients 
and healthy subjects (Beyazal et al., 2017). In this 
study, all patients were under treatment with DMARD 
as monotherapy or in combination whereas in our 
investigation, we classified patients in two separate 
groups including newly diagnosed patients and patients 
who received combinational DMARD including MTX 
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and HCQ plus prednisolone. Besides that, we could not 
find significant differences in plasma levels of TNF-α 
in our newly diagnosed RA compared with patients 
who were under treatment with MTX+HCQ+PSL. 
Similar result was observed in the study of Nishina et 
al. (2013) which revealed that monotherapy with MTX 
does not have any effect on plasma TNF-α levels. As 
MTX is the cornerstone of combinational DMARD 
therapy, it can be concluded that TNF-α is not the 
main target of this regimen. Recently, Nishina et al. 
(2013) demonstrated that following MTX therapy, the 
plasma levels of IL-6 but not TNF-α will be reduced 
(Nishina et al., 2013). In the following, we evaluated 
the association between plasma levels of TNF-α and 
RA disease activity in newly diagnosed RA patients 
as well as patients with established RA who received 
therapy. Previous studies showed a positive correlation 
between plasma levels of TNF-α and disease activity 
in RA patients, but we just observed this positive 
correlation in the newly diagnosed patients, not in 
patients who were undertreatment (Xia et al., 2015). 
In the newly diagnosed patient, the concentration of 
plasma TNF-α was significantly lower in sub-group 
with low disease activity compared with the sub-
groups with the moderate and high disease activity. It 
can be concluded that TNF-α has an important role 
in the early pathologic events of arthritis in naïve RA 
patients. Our finding is supported by previous data 
which shows that early aggressive treatment with 
TNF-α inhibitors and MTX causes durable remission 
in RA patients (Quinn et al., 2005). Moreover animal 
study demonstrated that the TNF-α is the principal 
cytokine in the early acute inflammatory process of RA 
and IL-1β has an important role in the maintenance of 
ensuing inflammatory reactions (Joosten et al., 1999). 
Interestingly, the previous study revealed that the 
TNF-α triggers a cascade of inflammatory cytokines 
release in the synovium of new-onset RA patients, in 
such a way that neutralization of TNF-α can prevent the 
production of IL-1 and IL-6, two important cytokines 
in the pathogenesis of RA (Butler et al., 1995).
CONCLUSION
Plasma levels of TNF-α have a significant 
correlation with disease activity in new-onset RA and 
it can be concluded that targeting TNF-α in the early 
stage of RA could have a more beneficial therapeutic 
outcome.
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